ηγωεϊ εδεγςεϊ μςιϊεπεϊ
θας ξγεεηϊ ςμ δϊεφΰεϊ μψαςεο δωπι ωμ 200701/8/2007 θας ϊςωιεϊ τψξφαθιεϊ ας"ξ γιεεηδ διεν ςμ ϊεφΰεϊ δψαςεο δωπι ωδρϊιιν α- 30 αιεπι, 2007.
ςιχψι δϊεφΰεϊ
ωιΰ αξλιψεϊ αψαςεο δωπι - 2,386 ξμιεο $, βιγεμ ωμ 10% αδωεεΰδ μψαςεο δωπι ΰωϊχγ, ψαςεο ΰωψ λμμ ΰϊ δδωχεϊ αξρβψϊ αμςγιεϊ ωμ Simvastatin ε- Pravastatin, ωϊιιν ξδδωχεϊ δβγεμεϊ αιεϊψ αδιρθεψιδ ωμ δϊςωιιδ.
δψεεη δπχι δρϊλν α- 515 ξμιεο $ αδωεεΰδ μψεεη πχι ωμ 489 ξμιεο $ εψεεη πχι ξϊεΰν ωμ 541 ξμιεο $ αψαςεο δξχαιμ ωμ 2006.
ψεεη μξπιδ αγιμεμ ωμ 0.63$ αδωεεΰδ μψεεη μξπιδ ωμ 0.59$ εψεεη ξεϊΰν ξγεμμ μξπιδ ωμ 0.66$ αψαςεο δξχαιμ ΰωϊχγ.
"διδ ζδ ψαςεο ξφειο μθας", ΰξψ ωμξδ ιπΰι, πωιΰ εξπλ"μ θας "ΰπε αξιεηγ ξψεφιν ξδξλιψεϊ ωεαψεϊ δωιΰιν ωμπε, δξωχτεϊ βιγεμ ωμ 10% αδωεεΰδ μψαςεο δωπι ωμ 2006, ωλμμ ωϊιιν ξδδωχεϊ δβγεμεϊ αιεϊψ αδιρθεψιδ ωμ δηαψδ ωμπε εωμ δϊςωιιδ λεμδ. ϊεφΰεϊ δψαςεο δεωτςε ξαιφεςιν ηζχιν αλμ διηιγεϊ δςρχιεϊ εαλμ δΰιζεψιν, ξξλιψεϊ ωιΰ ωμ χετχρεο® εξδωχδ ξεχγξϊ εξεφμηϊ αιεϊψ ωμ Amlodipine/Benazepril".
πϊεπιν τιππριν εΰιψεςιν ηωεαιν περτιν ωμ δψαςεο δωπι
δξλιψεϊ πθε ωμ δψαςεο δωπι δρϊλξε α- 2,386 ξμιεο $, βιγεμ ωμ 10% αδωεεΰδ μ- 2,172 ξμιεο $ αψαςεο δωπι ωμ 2006 εβιγεμ ωμ 15% αδωεεΰδ μψαςεο δψΰωεο ωμ 2007.
ψεεη πχι μψαςεο δρϊλν α- 515 ξμιεο $ ΰε 0.63$ ψεεη πχι ξγεμμ μξπιδ, αδωεεΰδ μψεεη πχι ωμ 489 ξμιεο $ ΰε 0.59$, ψεεη πχι ξγεμμ μξπιδ, εμψεεη πχι ξϊεΰν ωμ 541 ξμιεο $ ΰε 0.66$ ψεεη πχι ξγεμμ μξπιδ αψαςεο δξχαιμ ΰωϊχγ. ψεεη πχι αψαςεο δωπι διδ βαεδ α- 51% ξΰωψ αψαςεο δψΰωεο ωμ 2007. δψεεη δπχι δξϊεΰν αψαςεο δωπι ωμ 2006 μΰ λμμ: 31 ξμιεο $ αβιο ωιςψεκ ξμΰι δχωεψιν μψλιωϊ Ivax, 28 ξμιεο $ αβιο δεφΰεϊ δχωεψεϊ μιψιγϊ ςψκ εδεφΰεϊ ψδ ΰψβεο ε- 5 ξμιεο $ αβιο ξε"τ αϊδμικ αηαψεϊ χωεψεϊ. αρδ"λ δρϊλξε δεφΰεϊ ΰμε μΰηψ ξρ αρλεν ωμ 52 ξμιεο $. πϊεπι 2006 δξϊεΰξιν ΰιπν ςμ-τι λμμι δηωαεπΰεϊ δξχεαμιν αΰψδ"α (US GAAP). θας ξΰξιπδ λι ΰι δλμμϊ δτψιθιν δπ"μ, ξριιςϊ μδαπδ θεαδ ιεϊψ ωμ δξωχιςιν ΰϊ δξβξεϊ δςρχιεϊ αηαψδ.
δξλιψεϊ αλμ ςρχιδ ωμ θας ξηευ μΰψδ"α δεωτςε μθεαδ ξωςψι ημιτιο, ΰωψ δςμε ΰϊ δξλιψεϊ α -69 ξμιεο $. ςν ζΰϊ, ςρχιπε ψωξε βν ςμιδ αδεφΰεϊ αωμ ϊπεγεϊ ωςψι δημιτιο λκ ωδωτςϊν ςμ δψεεη δϊτςεμι διϊδ ωεμιϊ.
δξλιψεϊ δτψξφαθιεϊ αφτεο ΰξψιχδ αψαςεο δωπι δρϊλξε α- 1,341 ξμιεο $ αδωεεΰδ μ- 1,260 ξμιεο $ αψαςεο δωπι ωμ ωπϊ 2006, ψαςεο ΰωψ λμμ ΰϊ δδωχεϊ δξωξςεϊιεϊ ωμ Simvastatin ε- Pravastatin. δψαςεο δωπι ωμ 2007 δεωτς μθεαδ ξδωχδ ξεχγξϊ ξδφτει ωμ Amlodipine/Benazepril, ξλιψεϊ βαεδεϊ αΰετο πιλψ ωμ Oxycodone, ξλιψεϊ βαεδεϊ ιεϊψ ωμ ξεφψιν πωιξϊιιν, αςιχψ ProAir, ξεφψ θας ωΰιπε ξαερρ CFC αΰψδ"α, λξε βν ξξλιψεϊ βαεδεϊ ιεϊψ ωμ χετχρεο®. αψαςεο δπεληι, δξλιψεϊ δτψξφαθιεϊ αφτεο ΰξψιχδ διεε 60% ξρκ λμ δξλιψεϊ δτψξφαθιεϊ ωμ δηαψδ.
ξλιψεϊ ωιΰ τψξφαθιεϊ αΰιψετδ ωμ 556 ξμιεο $, βιγεμ ωμ 13% αδωεεΰδ μψαςεο ωπι ΰωϊχγ. δεωτςπε ξαιφεςιν ηζχιν ωμ δςρχιν δβπψιν ααψιθπιδ, φψτϊ, ρτψγ εβψξπιδ λξε βν ξλιψεϊ βαεδεϊ ιεϊψ ωμ ξεφψιν πωιξϊιιν ααψιθπιδ. αψαςεο δπεληι, δξλιψεϊ δτψξφαθιεϊ αΰιψετδ διεε 25% ξρκ λμ δξλιψεϊ δτψξφαθιεϊ ωμ δηαψδ.
ξλιψεϊ τψξφαθιεϊ αιπμΰεξιεϊ, ΰωψ διεε 15% ξρκ λμ δξλιψεϊ δτψξφαθιεϊ ελεμμεϊ αςιχψ ΰϊ ΰξψιχδ δμθιπιϊ (6% ξρκ δξλιψεϊ δτψξφαθιεϊ), ιωψΰμ (4%) εξγιπεϊ ξψλζ εξζψη ΰιψετδ (4%), βγμε δψαςεο α- 26% εδρϊλξε α- 346 ξμιεο $. δβιγεμ δεωτς ξξλιψεϊ βαεδεϊ ιεϊψ αψεα δωεεχιν δςιχψιιν ωμ ΰιζεψιν ΰμε.
δξλιψεϊ δβμεαμιεϊ ωμ χετχρεο®, αξεπηι ξηιψ ξλιψδ μωεχ, δρϊλξε α- 436 ξμιεο $, βιγεμ ωμ 23% αδωεεΰδ μψαςεο δξχαιμ α- 2006, λεμμ βιγεμ ωμ 24% αΰψδ"α μ- 285 ξμιεο $ ωδεωτς ξςμιϊ ξηιψ εβιγεμ λξεϊι. δξλιψεϊ αξεπηι ξηιψ ξλιψδ μωεχ ξηευ μΰψδ"α, αςιχψ αΰιψετδ, βγμε α- 23% εδρϊλξε α- 151 ξμιεο $ ειιφβε αιφεςιν ξωετψιν αξρτψ ωεεχιν ΰιψετΰιν ξψλζιιν: βψξπιδ, φψτϊ, ρτψγ εαψιθπιδ.
®Azilect - δξεφψ δξχεψι δωπι ωμ θας, δξωικ ΰϊ ηγιψϊε δξεφμηϊ μωεχ λημετδ ιςιμδ μθιτεμ αξημϊ δτψχιπρεο αΰψδ"α εαΰιψετδ. δξλιψεϊ δβμεαμιεϊ αξεπηι ξηιψ ξλιψδ μωεχ αψαςεο δρϊλξε α- 28 ξμιεο $ αδωεεΰδ μ- 6 ξμιεο $ αψαςεο δωπι ωμ 2006. ΰζιμχθ® ξΰεωψ λςϊ μωιξεω α- 27 ξγιπεϊ.
δξλιψεϊ δβμεαμιεϊ ωμ ξεφψι δπωιξδ δρϊλξε α- 181 ξμιεο $ αψαςεο δωπι ωμ 2007, βιγεμ ωμ 49% αιηρ μϊχετδ δξχαιμδ ΰωϊχγ. δβιγεμ πας αψεαε ξξλιψεϊ βαεδεϊ ωμ ProAir HFA αΰψδ"α εξξλιψεϊ βαεδεϊ ααψιθπιδ.
ξλιψεϊ δλιξιδ (API) μφγγιν ωμιωιιν, δρϊλξε α- 143 ξμιεο $ αψαςεο δωπι ωμ 2007, αδωεεΰδ μ- 145 ξμιεο $ αψαςεο δωπι ωμ 2006. λμμ ξλιψεϊ δ- API, λεμμ ξλιψεϊ μιηιγεϊ δτπιξιεϊ ωμ θας, δρϊλξε α- 334 ξμιεο $ δψαςεο, ιψιγδ ωμ 6% αδωεεΰδ μψαςεο δξχαιμ ΰωϊχγ.
δεφΰεϊ ξηχψ ετιϊεη (ξε"τ) πθε βγμε α - 14% αδωεεΰδ μψαςεο δξχαιμ α- 2006 εδρϊλξε α- 137 ξμιεο $, λΰωψ ιεϊψ ξξηφιϊ δο δεφΰεϊ ςμ ξε"τ βπψι.
μθας διε 153 αχωεϊ δξξϊιπεϊ μΰιωεψ ρετι ωμ ψωεϊ δξζεο εδϊψετεϊ δΰξψιχΰιϊ (FDA), πλεο μ- 30 αιεμι, 2007, ρκ δξλιψεϊ δωπϊιεϊ ωμ αχωεϊ ΰμδ, αξεπηι ξλιψεϊ ωπϊιεϊ ωμ δξεφψιν δξχεψιιν αΰψδ"α, διπε λ- 89 ξμιΰψγ $. θας ξΰξιπδ λι διπδ δψΰωεπδ μδβιω αχωδ μΰιωεψ ςαεψ 40 ξεφψιν ξϊεκ αχωεϊ ΰμδ, δξωχτιν ξλιψεϊ ωπϊιεϊ, αξεπηι ξλιψεϊ ωπϊιεϊ ωμ δξεφψιν δξχεψιιν αΰψδ"α, ωμ ξςμ μ- 37 ξμιΰψγ $. πλεο μ- 30 αιεπι, 2007, μθας διε 2,190 αχωεϊ δξξϊιπεϊ μΰιωεψ ρετι, δξωχτεϊ 280 τεψξεμφιεϊ ε- 134 ξεμχεμεϊ αξγιπεϊ ωεπεϊ ΰιψετδ.
δεφΰεϊ ξλιψδ, δπδμδ ελμμιεϊ (SG&A) ΰωψ διεε 19.7% ξδξλιψεϊ πθε δρϊλξε α- 469 ξμιεο $ αψαςεο δωπι αδωεεΰδ μ- 375 ξμιεο $ ΰε 17.3% ξδξλιψεϊ πθε αψαςεο δωπι ωμ 2006, ε- 456 ξμιεο $ αψαςεο δψΰωεο ωμ 2007. δβιγεμ μςεξϊ δψαςεο δξχαιμ ΰωϊχγ ξωχσ ημεχϊ ψεεη βγεμδ ιεϊψ ςν φγγιν ωμιωιιν λξε βν δεφΰεϊ ξλιψδ εωιεεχ δχωεψεϊ μξλιψεϊ δβγμεϊ ωμ ΰζιμχθ® εμτςιμεϊ δβπψιχδ δξξεϊβϊ δφεξηϊ ωμ θας.
ϊζψιν δξζεξπιν ξτςιμεϊ ωεθτϊ αψαςεο δωπι ωμ 2007 δρϊλν α- 437 ξμιεο $, αδωεεΰδ μ- 212 ξμιεο $ αψαςεο δωπι ωμ 2006. ϊζψιν ξζεξπιν ηετωι (Free Cash Flow) δρϊλν α- 256 ξμιεο $. ξζεξπιν επλριν πζιμιν ΰηψιν μιεν 30 αιεπι, 2007 δρϊλξε αλ- 3.1 ξμιΰψγ $.
γιαιγπγ
γιψχθεψιεο δηαψδ, αιωιαϊε αιεν 30 αιεμι, 2007, δλψιζ ςμ ϊωμεν γιαιγπγ αξζεξο ςαεψ δψαςεο δωπι ωμ 2007, αωιςεψ ωμ 0.40 ω"η μξπιδ (λ- 9.2 ρπθ ςμ τι ωςψ δγεμψ α- 30 αιεμι, 2007). διεν δχεας ιδιδ α- 14 αΰεβερθ, 2007 ειεν δϊωμεν πχας μ- 29 αΰεβερθ, 2007. ωιςεψ δξρ ωιπελδ αξχεψ ιδιδ 16%.
τψθι ωιηϊ δεςιγδ
δπδμϊ θας ϊχιιν ωιηϊ εςιγδ αιεν ψαιςι, 1 αΰεβερθ, 2007, αωςδ 15:30 ωςεο ιωψΰμ (08:30 ωςεο πιε-ιεψχ) ΰωψ αδ ιιρχψε ϊεφΰεϊ δψαςεο δωπι ωμ 2007. πιϊο μδΰζιο μωιηδ γψκ ΰϊψ δΰιπθψπθ ωμ θας, αλϊεαϊ : www.tevapharm.com. πιϊο ιδιδ μδΰζιο μωιγεψ ηεζψ ςγ μιεν 8 αΰεβερθ, 2007 αηφεϊ (ωςεο πιε-ιεψχ) αΰϊψ δηαψδ, ΰε ςμ-ιγι ηιεβ 1-877-660-6853 μξηιιβιν αϊεκ ΰψδ"α ε- 1-201-612-7415 μξηιιβιν ξηευ μΰψδ"α. χεγ δλπιρδ μωιγεψ δηεζψ διπε ηωαεο ξρτψ (Account #) 3055 ε- ϊε δζιδει (ID#) διπε: 248467.
ΰεγεϊ θας
θας ϊςωιεϊ τψξφαθιεϊ ας"ξ διπδ ηαψδ βμεαμιϊ ωαριρδ αιωψΰμ εΰηϊ ξ- 20 δηαψεϊ δτψξφαθιεϊ δξεαιμεϊ αςεμν. θας, δξϊξηδ αιιφεψ ϊψετεϊ βπψιεϊ ειιηεγιεϊ ειιφεψ ηεξψιν τςιμιν μϊςωιδ δτψξφαθιϊ, διπδ δηαψδ δξεαιμδ αςεμν αϊηεν δβπψιχδ. μθας ΰϊψι ιιφεψ, ξηχψ, ωιεεχ εδτφδ αιωψΰμ, αφτεο εαξψλζ ΰξψιχδ εαΰιψετδ. ιεϊψ ξ- 76% ξξλιψεϊιδ ωμ δχαεφδ δο μφτεο ΰξψιχδ εΰιψετδ.
μδμο δρςισ διγες αΰψδ"α λ- Safe Harbor απερηε δΰπβμι εΰωψ ξθψϊε μδβο ςμ δηαψδ, ςτ"ι δγιο δΰξψιχΰι:
Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: whether and when the proposed acquisition of CoGenesys will be consummated, whether and when Teva will obtain HSR approval for the acquisition and any conditions that could be imposed in connection with such approval, Teva's ability to rapidly integrate CoGenesys' operations with its own operations, the diversion of management time on merger-related issues, and Teva and CoGenesys' ability to successfully develop and commercialize biopharmaceutical products, Teva's ability to accurately predict future market conditions, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin®, Lotrel® Famvir®, and Protonix®, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: whether and when the proposed acquisition of CoGenesys will be consummated, whether and when Teva will obtain HSR approval for the acquisition and any conditions that could be imposed in connection with such approval, Teva's ability to rapidly integrate CoGenesys' operations with its own operations, the diversion of management time on merger-related issues, and Teva and CoGenesys' ability to successfully develop and commercialize biopharmaceutical products, Teva's ability to accurately predict future market conditions, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Allegra®, Neurontin®, Lotrel® Famvir®, and Protonix®, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which Teva may obtain U.S. market exclusivity for certain of its new generic products and regulatory changes that may prevent Teva from utilizing exclusivity periods, competition from brand-name companies that are under increased pressure to counter generic products, or competitors that seek to delay the introduction of generic products, the impact of consolidation of our distributors and customers, the effects of competition on our innovative products, especially Copaxone® sales, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, the regulatory environment and changes in the health policies and structures of various countries, our ability to achieve expected results though our innovative R&D efforts, Teva's ability to successfully identify, consummate and integrate acquisitions, potential exposure to product liability claims to the extent not covered by insurance, dependence on the effectiveness of our patents and other protections for innovative products, significant operations worldwide that may be adversely affected by terrorism, political or economical instability or major hostilities, supply interruptions or delays that could result from the complex manufacturing of our products and our global supply chain, environmental risks, fluctuations in currency, exchange and interest rates, and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
| © 1999 - 2008 λμ δζλειεϊ ωξεψεϊ μθας | ϊπΰι ωιξεω αΰϊψ | ξτϊ δΰϊψ |